Cardioversion Treatment in India
Get Cardioversion Treatment at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Cardioversion Treatment in UAE
Cardioversion Treatment at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Cardioversion is a precise cardiac rhythm-restoration procedure used to treat atrial fibrillation (AFib), atrial flutter, and other supraventricular tachyarrhythmias by delivering a controlled electrical shock or pharmacological agent to reset the heart's electrical conduction system. Clinical success rates for elective electrical cardioversion exceed 90% in appropriately selected patients, with sustained sinus rhythm at one year achievable in 50–70% of cases when combined with antiarrhythmic therapy. International patients choose GAF Healthcare to access board-certified electrophysiologists and state-of-the-art cardiac catheterization laboratories in India and the UAE at a fraction of Western costs, with seamless end-to-end medical coordination.
Hospital Stay: 1–2 days (outpatient or overnight observation) • Total Stay in Country (Fit-to-Fly): 1–2 weeks (subject to cardiologist clearance, anticoagulation stability, and absence of recurrent arrhythmia) • Success Rate: 90–95% (immediate restoration of sinus rhythm for elective electrical cardioversion)
What Is It?
Cardioversion is the therapeutic resetting of a pathological cardiac rhythm to normal sinus rhythm (NSR). The most common indication is atrial fibrillation, a disorganized atrial electrical activity affecting approximately 37 million people globally, which markedly elevates the risk of embolic stroke, heart failure, and hemodynamic compromise. In AFib, loss of coordinated atrial contraction reduces cardiac output by up to 20–30%, precipitating dyspnea, palpitations, fatigue, and in decompensated patients, cardiogenic shock. The CHA₂DS₂-VASc risk-scoring system is used universally to stratify thromboembolic risk prior to cardioversion planning.
Two primary modalities exist: electrical cardioversion (ECV) — also called synchronized direct-current cardioversion (DCCV) — and pharmacological cardioversion. In ECV, a biphasic defibrillator delivers a precisely timed, synchronized electrical impulse (typically 120–200 joules biphasic) that simultaneously depolarizes all myocardial cells, extinguishing the re-entrant circuits driving the arrhythmia and allowing the sinoatrial node to reassert physiological pacemaker control. Pharmacological cardioversion employs antiarrhythmic agents such as intravenous amiodarone, flecainide, propafenone, ibutilide, or vernakalant — selected based on the patient's structural heart disease profile and renal function.
The international standard of care, as defined by ACC/AHA/ESC guidelines, mandates a minimum of three weeks of therapeutic anticoagulation prior to elective cardioversion — or, alternatively, a transesophageal echocardiogram (TEE) to exclude left atrial appendage (LAA) thrombus — followed by a minimum of four weeks of anticoagulation post-procedure, regardless of apparent rhythm success. Long-term rhythm maintenance is typically achieved with antiarrhythmic drugs (class IC or III agents) or catheter ablation for patients with recurrent, drug-refractory AFib.
Candidates
• ELIGIBLE PATIENTS:
• Symptomatic atrial fibrillation (paroxysmal, persistent, or long-standing persistent) refractory to rate-control medications
• Atrial flutter with 2:1 or higher atrioventricular conduction causing hemodynamic symptoms
• Supraventricular tachycardias (SVTs) including AVNRT and AVRT not responsive to vagal maneuvers or adenosine
• Hemodynamically unstable tachyarrhythmias requiring urgent/emergent synchronized cardioversion
• Patients with heart failure exacerbated by tachyarrhythmia who may benefit from rhythm restoration
• Candidates for hybrid strategy: cardioversion followed by catheter ablation (pulmonary vein isolation) for durable rhythm control
• REQUIRED DIAGNOSTIC WORKUP:
• 12-lead ECG and 24–48 hour Holter monitoring to characterize arrhythmia type and burden
• Transthoracic echocardiogram (TTE) to assess left ventricular ejection fraction (LVEF), left atrial size, valvular pathology, and structural disease
• Transesophageal echocardiogram (TEE) to exclude left atrial appendage thrombus if cardioversion is planned without 3 weeks of prior anticoagulation
• Thyroid function tests (TSH/T4) — hyperthyroidism is a reversible precipitant
• Serum electrolytes (potassium, magnesium) — hypokalemia and hypomagnesemia increase arrhythmia risk and must be corrected pre-procedure
• Renal function panel (eGFR/creatinine) for anticoagulant dosing (DOACs: apixaban, rivaroxaban, edoxaban, dabigatran)
• CHA₂DS₂-VASc and HAS-BLED scoring for stroke and bleeding risk stratification
• Coronary artery disease workup (stress test or CT coronary angiography) if ischemic etiology is suspected
• CONTRAINDICATIONS:
• Confirmed left atrial appendage thrombus on TEE (absolute contraindication to elective ECV)
• Digitalis toxicity-induced arrhythmia (cardioversion may precipitate ventricular fibrillation)
• Sick sinus syndrome without permanent pacemaker backup (risk of prolonged asystole post-cardioversion)
• Severe, uncorrected hypokalemia or hypomagnesemia
• Active decompensated heart failure not responsive to initial stabilization
• Patient refusal or inability to tolerate conscious sedation/general anesthesia
• Severe aortic stenosis or other structural conditions where rhythm restoration alone is unlikely to provide hemodynamic benefit without definitive repair
Procedure
ELECTRICAL CARDIOVERSION (SYNCHRONIZED DCCV):
The gold-standard procedure for elective rhythm restoration. Performed under short-acting intravenous sedation (propofol, midazolam with fentanyl, or etomidate) to ensure patient comfort. Biphasic waveform defibrillators are exclusively used in modern practice — delivering 120–200 joules, biphasic waveforms require significantly less energy than monophasic and achieve higher first-shock success rates (>85% first shock, >95% cumulative). Electrode placement uses the standard anterolateral or anteroposterior configuration; anteroposterior positioning is preferred for patients with persistent AFib or elevated BMI due to superior transthoracic impedance. The defibrillator synchronizes the shock delivery to the R-wave of the ECG, preventing shock-on-T phenomenon that could induce ventricular fibrillation. Total procedure time: 15–30 minutes. Continuous cardiac monitoring and oxygen saturation monitoring are maintained throughout.
PHARMACOLOGICAL CARDIOVERSION:
Indicated for recent-onset AFib (<48 hours duration) in hemodynamically stable patients or as a bridge/adjunct to ECV. Agent selection is driven by structural heart disease status:
• No structural heart disease: Flecainide (oral 'pill-in-pocket' 200–300 mg, or IV) or Propafenone — high efficacy (45–70% conversion within 3–8 hours), contraindicated in structural heart disease
• Structural heart disease / reduced EF: IV Amiodarone (preferred; 150 mg bolus followed by infusion) — slower onset (hours to days) but safe across the broadest patient spectrum
• Acute setting (hospital use only): IV Ibutilide or Vernakalant — rapid onset (within 90 minutes), effective for recent-onset AFib and flutter; vernakalant is atrial-selective, reducing proarrhythmic risk
• Rate control pre-cardioversion: IV metoprolol, diltiazem, or digoxin as hemodynamically appropriate
HYBRID / ADVANCED RHYTHM CONTROL STRATEGIES:
For patients with recurrent AFib after successful cardioversion, catheter ablation — specifically pulmonary vein isolation (PVI) using radiofrequency energy (RF ablation) or cryoablation (Arctic Front Cryoballoon) — is offered as a definitive rhythm-control strategy. Leading cardiac centers in India and the UAE operate high-density 3D electroanatomical mapping systems (CARTO 3, EnSite Precision) to guide ablation with submillimeter precision, minimizing fluoroscopy time and improving procedural safety. For patients with concomitant left atrial appendage thrombus risk, percutaneous LAA occlusion (Watchman FLX device) may be combined with rhythm control, eliminating the need for long-term anticoagulation in eligible patients.
EMERGENCY / URGENT CARDIOVERSION:
Hemodynamically unstable patients (hypotension, acute pulmonary edema, altered consciousness) due to rapid tachyarrhythmia require immediate unsynchronized or synchronized cardioversion without delay for anticoagulation, under ACLS/ALS protocols. This is performed at bedside in the emergency department or ICU setting.
Cost of Cardioversion Treatment: India vs. UAE
The cost of cardioversion in Western countries such as the United States, United Kingdom, or Australia can range from USD 5,000 to over USD 15,000 when factoring in hospital facility fees, anesthesiology, cardiologist consultation, and post-procedure monitoring. India offers the same internationally accredited level of care — with NABH and JCI-accredited hospitals and fellowship-trained electrophysiologists — at 50–65% lower cost. The UAE provides a premium-tier experience with JCI-accredited facilities and Dubai Health Authority (DHA)-regulated care, positioned between Indian and Western price points, making it an attractive destination for patients from Europe, Africa, and the Middle East who prioritize proximity and luxury amenities alongside clinical excellence.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $800 – $2,500 | ~56% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $2,000 – $5,500 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-PROCEDURE PREPARATION (2–4 weeks before, if elective):
• GAF Healthcare coordinates a complete pre-procedural workup via telemedicine review of existing records before travel
• Anticoagulation initiation: If not already anticoagulated, a DOAC (apixaban, rivaroxaban) or warfarin is started; INR target 2.0–3.0 for warfarin-treated patients; DOACs are preferred for most patients
• Minimum 3 weeks of documented therapeutic anticoagulation required OR TEE exclusion of LAA thrombus
• Electrolyte correction, thyroid normalization, and optimization of comorbidities (blood pressure, heart failure)
• Pre-procedure fasting: 6 hours for solids, 2 hours for clear liquids (per ASA guidelines for sedation)
• Patient arrives at hospital on day of procedure; anesthesiology pre-assessment completed
PHASE 2 — THE PROCEDURE (Day 1):
• IV access established; baseline 12-lead ECG, vital signs, SpO₂ monitoring
• Short-acting IV sedation administered by anesthesiologist (procedural sedation or monitored anesthesia care)
• Electrode pads applied (anterolateral or anteroposterior configuration)
• Biphasic defibrillator synchronized to ECG R-wave
• Cardioversion delivered at 120–200 joules (escalating if initial attempt unsuccessful)
• Immediate post-shock ECG obtained to confirm sinus rhythm restoration
• Patient monitored in recovery for 2–4 hours; cardiac rhythm, blood pressure, and oxygen saturation observed
• Same-day discharge is standard for uncomplicated elective cases; overnight admission for patients with reduced LVEF, complex comorbidities, or those requiring IV antiarrhythmic initiation
PHASE 3 — IMMEDIATE POST-PROCEDURE (Days 1–7):
• Continuous anticoagulation maintained for minimum 4 weeks post-cardioversion (regardless of success) — risk of LAA stunning and delayed thrombus formation
• Antiarrhythmic drug initiated or continued (amiodarone, flecainide, sotalol, or dronedarone depending on structural heart disease profile)
• Outpatient follow-up ECG at 24–48 hours to confirm sustained sinus rhythm
• Activity: Light daily activities permitted immediately; avoid strenuous exertion for 5–7 days
• No driving for 24–48 hours post-sedation
• Skin: Mild chest wall erythema at electrode pad sites is normal; resolves within 48–72 hours
PHASE 4 — DISCHARGE & FIT-TO-FLY ASSESSMENT (Day 7–14):
• GAF Healthcare cardiologist performs a follow-up TTE and 12-lead ECG at Day 7
• Anticoagulation compliance and DOAC/warfarin levels verified
• International flight clearance issued when: (a) sustained sinus rhythm confirmed, (b) anticoagulation therapeutic and tolerated, (c) no hemodynamic compromise, and (d) patient comfortable with self-medication management during travel
• Most uncomplicated patients are cleared to fly at 7–10 days post-procedure
• GAF Healthcare provides a comprehensive medical discharge summary and prescription letter for customs/immigration
PHASE 5 — LONG-TERM FOLLOW-UP (1–6 months):
• Remote cardiac monitoring (wearable ECG patch / smartphone-based Kardia device) arranged through GAF Healthcare's telemedicine platform
• INR or DOAC compliance review at 4 weeks
• Decision on long-term anticoagulation continuation based on CHA₂DS₂-VASc score (anticoagulation is typically continued indefinitely for CHA₂DS₂-VASc ≥2 in men, ≥3 in women, regardless of apparent rhythm success)
• Assessment for catheter ablation if recurrence occurs within 3–6 months
Risks & Considerations
Cardioversion is a low-risk procedure with a strong safety profile when performed in an appropriately equipped cardiac facility by trained electrophysiologists; however, patients should be candidly informed of the following procedure-specific risks:
Thromboembolic stroke (0.1–0.7%): The most serious risk. Occurs due to dislodgment of a pre-existing left atrial appendage thrombus or LAA stunning post-cardioversion. This risk is effectively mitigated by adherence to the standard-of-care anticoagulation protocol (≥3 weeks pre-procedure or TEE exclusion of thrombus, plus ≥4 weeks post-procedure).
Top Hospitals for Cardioversion Treatment
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Apollo Hospitals
New Delhi, India
Fortis Memorial Research Institute
Gurgaon, India
Medanta - The Medicity
Gurgaon, India
Kokilaben Dhirubhai Ambani Hospital
Mumbai, India
Top Doctors for Cardioversion Treatment
Internationally trained specialists in Cardiology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Krishna S Iyer
MBBS, MS (Surgery), M.Ch (Cardiothoracic Surgery), Fellowship in Infant Cardiac Surgery
Pediatric Cardiac Surgeon
Fortis Escorts Heart Institute, New Delhi, India
35+ Yearsof experience
Dr. Krishna S Iyer is one of India's most experienced and internationally recognised pediatric cardiac surgeons. As Executive Director of Pediatric and Congenital Heart Surgery at Fortis Escorts Heart Institute in Okhla, New Delhi, he has devoted his career to giving children with congenital heart disease — some of the most complex and delicate patients in all of medicine — the best possible chance at a full life. After his medical training, Dr. Iyer… Read more
Dr. Devi Shetty
MBBS, MS (General Surgery), MCh (Cardiothoracic Surgery), Fellowship in Cardiac Surgery
Cardiac Surgeon
Narayana Health, Bengaluru, India
38+ Yearsof experience
Dr. Devi Prasad Shetty is one of the most respected and widely recognised cardiac surgeons in the world. He is the founder and chairman of Narayana Health, a hospital chain that has redefined what affordable, high-quality cardiac care looks like — not only in India, but globally. Early in his career, Dr. Shetty trained at Guy's Hospital in London, one of the oldest teaching hospitals in Britain. He later served as personal physician to Mother Teresa, an… Read more
Dr. Naresh Trehan
MBBS, MS (General Surgery), Fellowship in Cardiothoracic Surgery
Cardiothoracic Surgeon
Medanta – The Medicity, Gurgaon, India
40+ Yearsof experience
Dr. Naresh Trehan is widely regarded as one of the most accomplished cardiovascular and cardiothoracic surgeons of his generation. With more than four decades of clinical practice spanning India and the United States, he has performed over 48,000 cardiac surgeries and has consistently ranked among the best heart surgeons in Asia. Born and educated in India, Dr. Trehan completed his advanced surgical training at New York University Medical Center, where he… Read more
Dr. Z S Meharwal
MBBS, MS (Surgery), MCh (Cardiothoracic Surgery), MNAMS
Cardiothoracic Surgeon
Fortis Escorts Heart Institute, New Delhi, India
30+ Yearsof experience
Dr. Z S Meharwal is part of the founding team of doctors at Fortis Escorts Heart Institute in Okhla, New Delhi, one of India's most respected cardiac centres. With more than 30 years of experience in cardiac surgery and over 30,000 surgeries to his credit — including many of the most complex heart operations performed in the country — he stands as one of the most accomplished cardiothoracic surgeons of his generation. Dr. Meharwal is a pioneer in many new… Read more
Dr. Ritwick Raj Bhuyan
MBBS, MS (Surgery), M.Ch (Cardiothoracic Surgery), Senior Registrar – CTVS, Visiting Fellowship (Heart Transplant & VAD)
Cardiothoracic Surgeon
Fortis Escorts Heart Institute, New Delhi, India
20+ Yearsof experience
Dr. Ritwick Raj Bhuyan is a Cardiothoracic and Vascular Surgeon with 20 years of working experience in high-volume cardiothoracic centres in India and Australia. Currently serving as Director of Cardio Thoracic Vascular Surgery at Fortis Escorts Heart Institute in Okhla, New Delhi, he has been associated with nearly 15,000 open heart procedures and has performed more than 7,000 open heart surgeries independently — a figure that places him among the most… Read more
Frequently Asked Questions — Cardioversion Treatment
The all-inclusive cost of elective electrical cardioversion (DCCV) in India typically ranges from USD 800 to USD 2,500, covering cardiologist and anesthesiologist fees, the procedure in a catheterization laboratory or cardiac procedure suite, biphasic defibrillator use, short-acting IV sedation, monitoring, and a one-night hospital stay if required. This represents a saving of 50–70% compared to equivalent care in Western countries. In the UAE (Dubai or Abu Dhabi), the same procedure in JCI-accredited hospitals with DHA-regulated physicians ranges from USD 2,000 to USD 5,500, reflecting the higher facility and staffing costs in the Gulf region but still offering significant savings versus the United States or United Kingdom. Note that if the cardioversion is performed as part of a broader management package — including a pre-procedure transesophageal echocardiogram (TEE), antiarrhythmic drug initiation, or same-admission electrophysiology study — total costs will be higher in both destinations and will be quoted individually by GAF Healthcare based on the patient's specific clinical workup.
Most uncomplicated elective cardioversion patients are cleared to fly internationally within 7 to 10 days of the procedure. The mandatory pre-flight period serves several critical clinical purposes: first, sustained restoration of sinus rhythm must be confirmed on a follow-up 12-lead ECG and, where indicated, a repeat transthoracic echocardiogram (TTE); second, anticoagulation must be verified as therapeutic and well-tolerated — a critical window given the 4-week minimum post-cardioversion anticoagulation requirement; and third, the patient must be hemodynamically stable and confident in self-managing their oral antiarrhythmic and anticoagulant medications during a long-haul flight. Patients with reduced left ventricular ejection fraction, recurrent arrhythmia, or sedation-related complications may require an extended stay of up to 2 weeks. GAF Healthcare's treating electrophysiologist issues a formal fit-to-fly certificate and provides a detailed medical letter including the patient's rhythm status, medication list, and emergency contact details for the cardiac team, which the patient carries on board.
The immediate success rate of elective electrical cardioversion (synchronized DCCV) for atrial fibrillation — defined as restoration of sinus rhythm at the end of the procedure — is 90–95% with modern biphasic defibrillators when patients are appropriately selected and adequately anticoagulated. For atrial flutter, immediate cardioversion success rates exceed 95%. Pharmacological cardioversion with intravenous agents such as flecainide, ibutilide, or vernakalant has an immediate conversion rate of 45–75% for recent-onset AFib, depending on the agent and duration of arrhythmia. The longer-term picture is important for patient counseling: without adjunctive antiarrhythmic drug therapy, approximately 50% of patients experience AFib recurrence within 12 months. With antiarrhythmic drugs (amiodarone, flecainide, dronedarone), sustained sinus rhythm at 1 year is achieved in 55–70% of patients. For patients requiring durable rhythm control, catheter ablation (pulmonary vein isolation) — available at GAF Healthcare's partner centers in India and the UAE — offers 60–80% freedom from AFib at 1 year after a single procedure, making it the most effective long-term rhythm-control strategy for paroxysmal and selected persistent AFib patients.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides comprehensive end-to-end non-medical support to ensure that the patient's travel experience is as seamless as the clinical care itself.
VISA & ENTRY DOCUMENTATION — INDIA: International patients traveling to India for cardioversion or associated cardiac care qualify for the e-Medical Visa (e-MV), which is issued online within 72 hours for nationals of over 150 eligible countries. The e-MV is valid for 60 days with triple-entry privileges. GAF Healthcare's documentation team prepares and submits the medical invitation letter from the treating hospital — a mandatory supporting document for the e-Medical Visa application — and guides patients through the online process step by step.
VISA & ENTRY DOCUMENTATION — UAE: Nationals of over 60 countries, including the European Union, United States, United Kingdom, Canada, and Australia, receive a visa-on-arrival or visa-free entry to the UAE for up to 30–90 days. Patients from other regions can obtain a UAE medical treatment visa or a standard tourist visa, which GAF Healthcare facilitates through its Dubai- and Abu Dhabi-based partner network. The UAE's Golden Visa program also provides long-stay options for patients requiring extended follow-up.
AIRPORT TRANSFERS & GROUND LOGISTICS: GAF Healthcare arranges private, air-conditioned medical-grade transport from the international airport directly to the partner hospital or pre-arranged accommodation for all patients. Return transfers post-discharge are equally coordinated. For patients who are outpatient post-cardioversion, comfortable private vehicles with wheelchair accessibility are available.
ACCOMMODATION FOR PATIENT ATTENDANTS: A medical companion or family member accompanying the patient is accommodated in pre-negotiated partner hotels adjacent to the treating hospital in both India (typically 3–5-star, USD 30–120/night in major Indian cities) and the UAE (typically 4–5-star, USD 100–350/night in Dubai or Abu Dhabi). GAF Healthcare negotiates preferential rates and handles all bookings.
MEDICAL TRANSLATION & CULTURAL SUPPORT: Dedicated multilingual patient coordinators are assigned to each case, available in English, Arabic, Russian, French, and other major languages. Medical interpretation is provided during all key consultations and discharge briefings to ensure the patient fully understands their post-procedure anticoagulation regimen and follow-up plan.
TELEMEDICINE & POST-RETURN FOLLOW-UP: All GAF Healthcare patients receive access to a remote cardiology follow-up consultation at 4 weeks and 3 months post-procedure via a secure video platform, allowing the treating electrophysiologist to review remote ECG monitoring data, anticoagulation labs, and symptom reports without requiring the patient to travel back.
Patients Also Explore
Other treatments commonly sought by patients considering Cardioversion Treatment.
Breast Cancer Treatment
Cancer Care
Lung Cancer Treatment
Cancer Care
Brain Tumor Surgery
Neurology
Deep Brain Stimulation
Neurology